Experiences with Citrate Rather Than Heparin as an Anticoagulant for 18F-FDG Labeling of Leukocytes

Journal of Nuclear Medicine Technology

Randi Moen Forfang¹  Signe E. Hagve¹  Merethe Wigen Andersen¹  Charlotte Eldjarn¹  Kjell Rootwelt¹ 

关键词: ¹⁸F-FDG–labeled leukocytes;    ¹⁸F-FDG–labeled white blood cells;    inflammation imaging;    vascular graft infection;   

DOI  :  10.2967/jnmt.110.085464

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

In all reported clinical studies with 18F-FDG–labeled leukocytes, heparin was used as an anticoagulant during labeling. Theoretically, the substitution of heparin with citrate should be advantageous. Methods: Blood from healthy controls was sampled in duplicate, anticoagulated with citrate or heparin, and labeled with 18F-FDG, and the labeling yield was measured. Viability was checked with the trypan blue exclusion technique. Moreover, 4 in vivo PET/CT studies were performed after the reinjection of leukocytes labeled after citrate anticoagulation. Results: The labeling yields obtained with citrate and heparin were not significantly different (P = 0.447). Viability was greater than or equal to 99%. The quality of the PET/CT studies was excellent. In the in vivo studies, the mean labeling yield was 78%better than or equal to that reported with heparin as an anticoagulant. Conclusion: Citrate is at least as effective as heparin as an anticoagulant, does not (unlike heparin) increase granulocyte activation, and should be the preferred anticoagulant for 18F-FDG labeling of leukocytes.

【 授权许可】

Unknown